Literature DB >> 28816543

MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A.

Liqin Ren1, Chunyan Yang1, Yongfeng Dou2, Renhui Zhan1, Yi Sun3, Yan Yu1.   

Abstract

AIM OF THE STUDY: Idiopathic pulmonary fibrosis (IPF) is a lethal human disease with short survival time and few treatment options. In this study, we aim to demonstrate that cyclic nucleotide phosphodiesterase 1A (PDE1A), a Ca2+/calmodulin-stimulating PDE family member, plays a critical role in the induction of fibrosis and angiogenesis in the lung.
MATERIALS AND METHODS: To induce pulmonary damage, adult male SD rats were treated with bleomycin in a dose of 6 mg/kg body weight by a single intratracheal instillation. For in vivo silencing of PDE1A in rat lung, a nonspecific control siRNA or PDE1A-specific siRNA was used to treat rat through nasal instillation. Human normal pulmonary fibroblasts MRC-5 and hFL1 and rat lung fibroblasts were used as in vitro model. Immunohistochemistry and immunoflurescence staining were performed to detect PDE1A and α-SMA expression. Reverse transcription-qPCR was performed to detect microRNA and mRNA expression. In vitro wound healing assay was performed to detect pulmonary fibroblasts'mortality ability.
RESULTS: In vitro studies showed that PDE1A can stimulate lung fibroblasts to undergo myofibroblastic changes. This led to the identification of miR-541-5p as one of the miRNA candidates associated with bleomycin response. We found that miR-541-5p expression is downregulated in TGF-β-treated lung fibroblasts and the rat pulmonary fibrosis model. Overexpression of miR-541-5p in lung fibroblasts inhibited mortality of human lung fibroblasts.
CONCLUSIONS: MiR-541-5p is a key effector in lung fibroblastsby by regulating PDE1A expression at protein translation level and its overexpression is protective against bleomycin-induced lung fibrosis.

Entities:  

Keywords:  lung fibrosis; microRNA; myofibroblast; phosphodiesterase 1A

Mesh:

Substances:

Year:  2017        PMID: 28816543     DOI: 10.1080/01902148.2017.1349210

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  6 in total

1.  MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.

Authors:  Suzan M Mansour; Hanan S El-Abhar; Ayman A Soubh
Journal:  Inflammopharmacology       Date:  2020-09-10       Impact factor: 4.473

Review 2.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 3.  The function of non-coding RNAs in idiopathic pulmonary fibrosis.

Authors:  Hui Zhang; Miao Song; Jianing Guo; Junbing Ma; Min Qiu; Zheng Yang
Journal:  Open Med (Wars)       Date:  2021-03-26

4.  Irradiation Activates MZF1 to Inhibit miR-541-5p Expression and Promote Epithelial-Mesenchymal Transition (EMT) in Radiation-Induced Pulmonary Fibrosis (RIPF) by Upregulating Slug.

Authors:  Xinxin Liang; Ziyan Yan; Ping Wang; Yuhao Liu; Xingkun Ao; Zheng Liu; Duo Wang; Xiaochang Liu; Maoxiang Zhu; Shanshan Gao; Dafei Xie; Pingkun Zhou; Yongqing Gu
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

5.  Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile.

Authors:  Serena Vella; Pier Giulio Conaldi; Emanuela Cova; Federica Meloni; Rosa Liotta; Salvatore Cuzzocrea; Lavinia Martino; Alessandro Bertani; Angelo Luca; Patrizio Vitulo
Journal:  Sci Rep       Date:  2018-07-24       Impact factor: 4.379

6.  MicroRNA-541-5p REgulates Type II Alveolar Epithelial Cell Proliferation and Activity by Modulating the HMGB1 Expression.

Authors:  Jie Shen; Jun Yan; Qiuyun Wang; Lei Zhuang; Yan Luo
Journal:  Shock       Date:  2022-04-01       Impact factor: 3.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.